Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/8/2025

Risperidone Discontinuation Guidelines

Rationale for Tapering

  • The American Academy of Child and Adolescent Psychiatry recommends slow tapering of antipsychotics like risperidone to avoid rebound worsening of symptoms and withdrawal symptoms 1, 2
  • Gradual tapering is necessary to prevent rapid return or worsening of underlying psychiatric conditions, such as psychosis, mania, or tic disorders 1, 2
  • The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, suggests reducing the dose gradually over several weeks, starting with a 25% decrease of the original dose, and maintaining this for 1-2 weeks 3
  • Continue reducing the dose by 25% increments every 1-2 weeks as tolerated, and slow the taper rate or temporarily return to the previous dose if withdrawal symptoms or psychiatric symptom recurrence occurs 3
  • Very slow tapers, with 10% reductions per month, may be necessary for patients on long-term treatment or those experiencing intolerable symptoms 3

Monitoring During Discontinuation

  • The American Academy of Child and Adolescent Psychiatry recommends establishing a structured monitoring plan before starting the taper, including scheduling weekly follow-up visits to assess for symptom return and withdrawal effects 4
  • Monitor for return of original psychiatric symptoms, which may emerge weeks to months after the last dose, and watch for withdrawal symptoms including anxiety, insomnia, agitation, and physical discomfort 5, 2

Critical Cautions

  • The American Academy of Child and Adolescent Psychiatry advises against abrupt discontinuation of risperidone, except in medical emergencies, due to the risk of rapid clinical deterioration and psychotic exacerbations 1, 2
  • Patients who have been on risperidone for extended periods require especially gradual tapers to minimize the risk of symptom rebound 3
  • If severe psychiatric symptoms return during tapering, reinstate the previous effective dose and consult a psychiatrist before attempting further discontinuation 5, 1

REFERENCES

1

practice parameter on the use of psychotropic medication in children and adolescents. [LINK]

Journal of the American Academy of Child and Adolescent Psychiatry, 2009

2

practice parameter on the use of psychotropic medication in children and adolescents. [LINK]

Journal of the American Academy of Child and Adolescent Psychiatry, 2009

4

Cross-Tapering from Duloxetine to Venlafaxine [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

practice parameter on the use of psychotropic medication in children and adolescents. [LINK]

Journal of the American Academy of Child and Adolescent Psychiatry, 2009